<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37326935</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1590-3478</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology</Title><ISOAbbreviation>Neurol Sci</ISOAbbreviation></Journal><ArticleTitle>Is there a treatment effective and safe for sialorrhea in people with amyotrophic lateral sclerosis (ALS)? Summary of a Cochrane Systematic Review.</ArticleTitle><Pagination><StartPage>3083</StartPage><EndPage>3085</EndPage><MedlinePgn>3083-3085</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10072-023-06881-y</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cantisani</LastName><ForeName>Teresa Anna</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Cochrane Neurological Sciences Field, Perugia, Italy. teresaanna.cantisani@ospedale.perugia.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit of Neurophysiopathology, Perugia Hospital, Perugia, Italy. teresaanna.cantisani@ospedale.perugia.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Neurol Sci</MedlineTA><NlmUniqueID>100959175</NlmUniqueID><ISSNLinking>1590-1874</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.24.69</RegistryNumber><NameOfSubstance UI="D001905">Botulinum Toxins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>J Pain Symptom Manage. 2022 Apr;63(4):e387-e396</RefSource><PMID Version="1">34920148</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001905" MajorTopicYN="Y">Botulinum Toxins</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012798" MajorTopicYN="Y">Sialorrhea</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000078202" MajorTopicYN="N">Systematic Reviews as Topic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>16</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>16</Day><Hour>11</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37326935</ArticleId><ArticleId IdType="doi">10.1007/s10072-023-06881-y</ArticleId><ArticleId IdType="pii">10.1007/s10072-023-06881-y</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Garuti G, Rao F, Ribuffo V, Sansone VA (2019) Sialorrhea in patients with ALS: current treatment options. Degener Neurol Neuromuscul Dis 20(9):19&#x2013;26. https://doi.org/10.2147/DNND.S168353</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DNND.S168353</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Yang X, Han Q, Liu M, Zhou C (2022) Prevalence of Sialorrhea Among Amyotrophic Lateral Sclerosis Patients: A Systematic Review and Meta-Analysis. J Pain Symptom Manage 63(4):e387&#x2013;e396. https://doi.org/10.1016/j.jpainsymman.2021.12.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpainsymman.2021.12.005</ArticleId><ArticleId IdType="pubmed">34920148</ArticleId></ArticleIdList></Reference><Reference><Citation>James E, Ellis C, Brassington R, Sathasivam S, Young CA (2022) Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis. Cochrane Database Syst Rev 5(5):CD006981. https://doi.org/10.1002/14651858.CD006981.pub3</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD006981.pub3</ArticleId><ArticleId IdType="pubmed">35593746</ArticleId></ArticleIdList></Reference><Reference><Citation>https://www.ema.europa.eu/en/medicines/human/EPAR/nuedexta#authorisation-details-section</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>